ESG Report

Overview

The report presents Clarity Pharmaceuticals' ESG practices for FY2022-2023, highlighting a six-product clinical pipeline, seven active oncology trials and compassionate access programs. It reports 41 employees across Australia and the US, with a 61% female workforce and 29% female board. The report also highlights Australian research partnerships, community initiatives supporting childhood cancer and Indigenous youth, and environmental advantages from its copper-isotope platform. ESG integration responsibility is assigned to the Board.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2022-2023
Period: 1 July 2022 – 30 June 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services